Ryan Scott

Combination therapy with the novel agent BXCL701 and pembrolizumab showed strong clinical activity in in patients with platinum-resistant small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer.

Baseline findings showed that patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance experienced a complete response rate of 13% and a partial response rate of 68% to chemotherapy.

The utilization of sabizabulin in patients yielded significant and durable objective tumor responses, according to results of a phase 1b/2 trial (NCT03752099) presented at the 2022 AUA Annual Meeting.

Ziad Bakouny, MD, MSc, highlights efforts to gain an understanding of the biology and genomic drivers of the rare and aggressive form of kidney cancer.